Combination chemotherapy for mycosis fungoides: A southwest oncology group study

P. N. Grozea, S. E. Jones, E. M. McKelvey, C. A. Coltman, R. Fisher, C. L. Haskins

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Between 1972 and 1977, the Southwest Oncology Group studied the following three chemotherapy programs for the treatment of patients with advanced forms of mycosis fungoides: cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) (seven patients); adriamycin, vincristine, and prednisone (HOP) (five patients); and cyclophosphamide, vincristine, prednisone, and bleomycin (COP plus bleomycin) (12 patients). Among the 24 evaluable patients there was an overall objective response rate of 95% with seven (29%) achieving a complete remission. With the adriamycin-containing chemotherapy, five (42%) of 12 patients achieved a complete remission compared to two (17%) of 12 patients treated with COP plus bleomycin. The median duration of remission (partial plus complete) was longer with the COP plus bleomycin combination (median, 47 weeks) than with the adriamycin-containing combinations (median, 22 weeks; P = 0.03). The median survival for all 24 evaluable patients was 95 weeks and was similar regardless of remission-induction therapy. In summary, combination chemotherapy proved to be effective palliative therapy for advanced mycosis fungoides.

Original languageEnglish (US)
Pages (from-to)647-653
Number of pages7
JournalCancer Treatment Reports
Issue number4
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combination chemotherapy for mycosis fungoides: A southwest oncology group study'. Together they form a unique fingerprint.

Cite this